MilliporeSigma, the U.S. and Canada life science business of Germany-based Merck, has received a $136.7 million federal contract for a new facility in Sheboygan that will produce a key ingredient used in rapid diagnostic test kits for COVID-19 and other infectious diseases.
To access this content, you must purchase a Premium membership, or log in if you are a member.